Skip to main content

Articles

Page 3 of 31

  1. Frailty and dementia have a bidirectional relationship. However, frailty is rarely reported in clinical trials for dementia and mild cognitive impairment (MCI) which limits assessment of trial applicability. T...

    Authors: Heather Wightman, Terry J. Quinn, Frances S. Mair, Jim Lewsey, David A. McAllister and Peter Hanlon
    Citation: Alzheimer's Research & Therapy 2023 15:110
    Content type: Research Published on:

  2. The correlations between genetic risk for Alzheimer’s disease (AD) with comprehensive brain regions at a regional scale are still not well understood. We aim to explore whether these associations vary across d...

    Authors: Xiao-Yu He, Bang-Sheng Wu, Kevin Kuo, Wei Zhang, Qing Ma, Shi-Tong Xiang, Yu-Zhu Li, Zi-yi Wang, Qiang Dong, Jian-Feng Feng, Wei Cheng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2023 15:109
    Content type: Research Published on:

  3. Chemokines, which are chemotactic inflammatory mediators involved in controlling the migration and residence of all immune cells, are closely associated with brain inflammation, recognized as one of the potent...

    Authors: Futao Zhou, Yangyan Sun, Xinhua Xie and Yushi Zhao
    Citation: Alzheimer's Research & Therapy 2023 15:107
    Content type: Review Published on:

  4. Rapidly progressive forms of Alzheimer’s disease (rpAD) are increasingly recognized and may have a prevalence of up to 30% of patients among all patients with Alzheimer’s disease (AD). However, insights about ...

    Authors: Janne Marieke Herden, Peter Hermann, Isabel Schmidt, Kathrin Dittmar, Sezgi Canaslan, Luise Weglage, Sabine Nuhn, Corinna Volpers, Astrid Schlung, Stefan Goebel, Fabian Kück, Anna Villar-Piqué, Christian Schmidt, Dirk Wedekind and Inga Zerr
    Citation: Alzheimer's Research & Therapy 2023 15:106
    Content type: Research Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:116

  5. Over recent years, increasing evidence suggests a causal relationship between neurofibrillary tangles (NFTs) formation, the main histopathological hallmark of tauopathies, including Alzheimer’s disease (AD), a...

    Authors: Carolina Bianchi, Beatriz Alvarez-Castelao, Álvaro Sebastián-Serrano, Caterina Di Lauro, Lucia Soria-Tobar, Annette Nicke, Tobias Engel and Miguel Díaz-Hernández
    Citation: Alzheimer's Research & Therapy 2023 15:105
    Content type: Research Published on:

  6. Authors: Francesca Conca, Valentina Esposito, Francesco Rundo, Davide Quaranta, Cristina Muscio, Rosa Manenti, Giulia Caruso, Ugo Lucca, Alessia Antonella Galbussera, Sonia Di Tella, Francesca Baglio, Federica L’Abbate, Elisa Canu, Valentina Catania, Massimo Filippi, Giulia Mattavelli…
    Citation: Alzheimer's Research & Therapy 2023 15:104
    Content type: Correction Published on:

    The original article was published in Alzheimer's Research & Therapy 2022 14:113

  7. White matter hyperintensities, a neuroimaging marker of small-vessel cerebrovascular disease and apolipoprotein ε4 (APOE4) allele, are important dementia risk factors. However, APOE4 as a key effect modifier i...

    Authors: Ashwati Vipin, Dilip Kumar, See Ann Soo, Fatin Zahra Zailan, Yi Jin Leow, Chen Ling Koh, Adeline Su Lyn Ng, Kok Pin Ng and Nagaendran Kandiah
    Citation: Alzheimer's Research & Therapy 2023 15:103
    Content type: Research Published on:

  8. The diagnosis of probable cerebral amyloid angiopathy (CAA) is currently mostly based on characteristics of brain MRI. Blood biomarkers would be a cost-effective, easily accessible diagnostic method that may c...

    Authors: Anna M. de Kort, H. Bea Kuiperij, Lieke Jäkel, Iris Kersten, Ingeborg Rasing, Ellis S. van Etten, Sanneke van Rooden, Matthias J. P. van Osch, Marieke J. H. Wermer, Gisela M. Terwindt, Floris H. B. M. Schreuder, Catharina J. M. Klijn and Marcel M. Verbeek
    Citation: Alzheimer's Research & Therapy 2023 15:102
    Content type: Research Published on:

  9. Increasing evidence links the gut microbiota (GM) to Alzheimer’s disease (AD) but the mechanisms through which gut bacteria influence the brain are still unclear. This study tests the hypothesis that GM and me...

    Authors: Moira Marizzoni, Peppino Mirabelli, Elisa Mombelli, Luigi Coppola, Cristina Festari, Nicola Lopizzo, Delia Luongo, Monica Mazzelli, Daniele Naviglio, Jean-Louis Blouin, Marc Abramowicz, Marco Salvatore, Michela Pievani, Annamaria Cattaneo and Giovanni B. Frisoni
    Citation: Alzheimer's Research & Therapy 2023 15:101
    Content type: Research Published on:

  10. Plasma amyloid-β (Aβ) peptides and tau proteins are promising biomarkers of Alzheimer’s disease (AD), not only for predicting Aβ and tau pathology but also for differentiating AD from other neurodegenerative d...

    Authors: Jingshan Chen, Xue Zhao, Wenyan Zhang, Tianxiang Zhang, Siting Wu, Jinghao Shao and Fu-Dong Shi
    Citation: Alzheimer's Research & Therapy 2023 15:100
    Content type: Research Published on:

  11. Cortical tau accumulation is a key pathological event that partly defines Alzheimer’s disease (AD) onset and is associated with cognitive decline and future disease progression. However, an improved understand...

    Authors: Antoinette O’Connor, David M. Cash, Teresa Poole, Pawel J. Markiewicz, Maggie R. Fraser, Ian B. Malone, Jieqing Jiao, Philip S. J. Weston, Shaney Flores, Russ Hornbeck, Eric McDade, Michael Schöll, Brian A. Gordon, Randall J. Bateman, Tammie L. S. Benzinger and Nick C. Fox
    Citation: Alzheimer's Research & Therapy 2023 15:99
    Content type: Research Published on:

  12. Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated. Results...

    Authors: Samuel P. Dickson, Sean Hennessey, Jessie Nicodemus Johnson, Newman Knowlton and Suzanne B. Hendrix
    Citation: Alzheimer's Research & Therapy 2023 15:98
    Content type: Review Published on:

  13. White matter hyperintensities (WMH) in subjects across the Alzheimer’s disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology—not just arterial hypertension—impacts WMH, which in...

    Authors: Jose Bernal, Stefanie Schreiber, Inga Menze, Anna Ostendorf, Malte Pfister, Jonas Geisendörfer, Aditya Nemali, Anne Maass, Renat Yakupov, Oliver Peters, Lukas Preis, Luisa Schneider, Ana Lucia Herrera, Josef Priller, Eike Jakob Spruth, Slawek Altenstein…
    Citation: Alzheimer's Research & Therapy 2023 15:97
    Content type: Research Published on:

  14. Carrying the apolipoprotein E (ApoE) Ɛ4 allele is associated with an increased risk of cerebral amyloidosis and late-onset Alzheimer’s disease, but the degree to which apoE glycosylation affects its developmen...

    Authors: Cristiana J. Meuret, Yueming Hu, Sabrina Smadi, Mikaila Ann Bantugan, Haotian Xian, Ashley E. Martinez, Ronald M. Krauss, Qiu-Lan Ma, Dobrin Nedelkov and Hussein N. Yassine
    Citation: Alzheimer's Research & Therapy 2023 15:96
    Content type: Research Published on:

  15. The purpose of this study was to evaluate cholesterol esterification and HDL subclasses in plasma and cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) patients.

    Authors: Marta Turri, Elisa Conti, Chiara Pavanello, Francesco Gastoldi, Marcella Palumbo, Franco Bernini, Vittoria Aprea, Francesca Re, Alberto Barbiroli, Davide Emide, Daniela Galimberti, Lucio Tremolizzo, Francesca Zimetti and Laura Calabresi
    Citation: Alzheimer's Research & Therapy 2023 15:95
    Content type: Research Published on:

  16. Neuropsychiatric symptoms (NPS) are prevalent in the early clinical stages of Alzheimer’s disease (AD) according to proxy-based instruments. Little is known about which NPS clinicians report and whether their ...

    Authors: Willem S. Eikelboom, Ellen H. Singleton, Esther van den Berg, Casper de Boer, Michiel Coesmans, Jeannette A. Goudzwaard, Everard G. B. Vijverberg, Michel Pan, Cornalijn Gouw, Merel O. Mol, Freek Gillissen, Jay L. P. Fieldhouse, Yolande A. L. Pijnenburg, Wiesje M. van der Flier, John C. van Swieten, Rik Ossenkoppele…
    Citation: Alzheimer's Research & Therapy 2023 15:94
    Content type: Research Published on:

  17. APP duplication is a rare genetic cause of Alzheimer disease and cerebral amyloid angiopathy (CAA). We aimed to evaluate the phenotypes of APP duplications carriers.

    Authors: Lou Grangeon, Camille Charbonnier, Aline Zarea, Stephane Rousseau, Anne Rovelet-Lecrux, David Bendetowicz, Marion Lemaitre, Cécile Malrain, Muriel Quillard-Muraine, Kevin Cassinari, David Maltete, Jeremie Pariente, Olivier Moreaud, Eloi Magnin, Benjamin Cretin, Marie-Anne Mackowiak…
    Citation: Alzheimer's Research & Therapy 2023 15:93
    Content type: Research Published on:

  18. Studies on DNA methylation (DNAm) in Alzheimer’s disease (AD) have recently highlighted several genomic loci showing association with disease onset and progression.

    Authors: Yasmine Sommerer, Valerija Dobricic, Marcel Schilling, Olena Ohlei, Sanaz Sedghpour Sabet, Tanja Wesse, Janina Fuß, Sören Franzenburg, Andre Franke, Laura Parkkinen, Christina M. Lill and Lars Bertram
    Citation: Alzheimer's Research & Therapy 2023 15:92
    Content type: Research Published on:

  19. Monitoring the progression of Tau pathology makes it possible to study the clinical diversity of Alzheimer’s disease. In this 2-year longitudinal PET study, we aimed to determine the progression of [18F]-flortauc...

    Authors: Julien Lagarde, Pauline Olivieri, Matteo Tonietto, Sébastian Rodrigo, Philippe Gervais, Fabien Caillé, Martin Moussion, Michel Bottlaender and Marie Sarazin
    Citation: Alzheimer's Research & Therapy 2023 15:91
    Content type: Research Published on:

  20. Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer’s disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting an...

    Authors: Tobias Gustavsson, Nicole G. Metzendorf, Elin Wik, Sahar Roshanbin, Ulrika Julku, Aikaterini Chourlia, Per Nilsson, Ken G. Andersson, Hanna Laudon, Greta Hultqvist, Stina Syvänen and Dag Sehlin
    Citation: Alzheimer's Research & Therapy 2023 15:90
    Content type: Research Published on:

  21. It is possible to calculate the number of years to the expected clinical onset (YECO) of autosomal-dominant Alzheimer’s disease (adAD). A similar time scale is lacking for sporadic Alzheimer’s disease (sAD). T...

    Authors: Ove Almkvist and Agneta Nordberg
    Citation: Alzheimer's Research & Therapy 2023 15:89
    Content type: Research Published on:

  22. Recruiting to multi-site trials is challenging, particularly when striving to ensure the randomized sample is demographically representative of the larger disease-suffering population. While previous studies h...

    Authors: Dylan R. Kirn, Joshua D. Grill, Paul Aisen, Karin Ernstrom, Seth Gale, Judith Heidebrink, Gregory Jicha, Gustavo Jimenez-Maggiora, Leigh Johnson, Elaine Peskind, Kelly McCann, Elizabeth Shaffer, David Sultzer, Shunran Wang, Reisa Sperling and Rema Raman
    Citation: Alzheimer's Research & Therapy 2023 15:88
    Content type: Research Published on:

  23. Therapeutic trials in Alzheimer’s disease (AD) face many obstacles—particularly with regard to screening and recruitment.

    Authors: Victoire Leroy, Wassim Gana, Amal Aïdoud, Jacques-Alexis N’kodo, Anna-Chloé Balageas, Pascal Blanc, Dominique Bomia, Camille Debacq and Bertrand Fougère
    Citation: Alzheimer's Research & Therapy 2023 15:87
    Content type: Debate Published on:

  24. Subjective cognitive decline (SCD) may serve as a symptomatic indicator for preclinical Alzheimer’s disease; however, SCD is a heterogeneous entity regarding clinical progression. We aimed to investigate wheth...

    Authors: Qian Chen, Futao Chen, Cong Long, Yajing Zhu, Yaoxian Jiang, Zhengyang Zhu, Jiaming Lu, Xin Zhang, Zuzana Nedelska, Jakub Hort and Bing Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:86
    Content type: Research Published on:

  25. Authors: Bruno Dubois, Jesús López‑Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine and Magda Tsolaki
    Citation: Alzheimer's Research & Therapy 2023 15:85
    Content type: Correction Published on:

    The original article was published in Alzheimer's Research & Therapy 2023 15:39

  26. Although machine learning classifiers have been frequently used to detect Alzheimer’s disease (AD) based on structural brain MRI data, potential bias with respect to sex and age has not yet been addressed. Her...

    Authors: Malte Klingenberg, Didem Stark, Fabian Eitel, Céline Budding, Mohamad Habes and Kerstin Ritter
    Citation: Alzheimer's Research & Therapy 2023 15:84
    Content type: Research Published on:

  27. The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screen...

    Authors: Rina Nakamura, Motomi Konishi, Youichirou Higashi, Motoaki Saito and Toshifumi Akizawa
    Citation: Alzheimer's Research & Therapy 2023 15:83
    Content type: Research Published on:

  28. The medial parietal cortex is an early site of pathological protein deposition in Alzheimer’s disease (AD). Previous studies have identified different subregions within this area; however, these subregions are...

    Authors: Dániel Veréb, Mite Mijalkov, Yu-Wei Chang, Anna Canal-Garcia, Emiliano Gomez-Ruis, Anne Maass, Sylvia Villeneuve, Giovanni Volpe and Joana B. Pereira
    Citation: Alzheimer's Research & Therapy 2023 15:82
    Content type: Research Published on:

  29. During COVID-19 lockdown measures, memory clinic patients reported worries for faster cognitive decline, due to loss of structure and feelings of loneliness and depression. We aimed to investigate the impact o...

    Authors: Els D. Bakker, Stéphanie L. van der Pas, Marissa D. Zwan, Freek Gillissen, Femke H. Bouwman, Philip Scheltens, Wiesje M. van der Flier and Ingrid S. van Maurik
    Citation: Alzheimer's Research & Therapy 2023 15:81
    Content type: Research Published on:

  31. Crucial to the success of clinical trials targeting early Alzheimer’s disease (AD) is recruiting participants who are more likely to progress over the course of the trials. We hypothesize that a combination of...

    Authors: Long Xie, Sandhitsu R. Das, Laura E. M. Wisse, Ranjit Ittyerah, Robin de Flores, Leslie M. Shaw, Paul A. Yushkevich and David A. Wolk
    Citation: Alzheimer's Research & Therapy 2023 15:79
    Content type: Research Published on:

  32. Growing evidence has demonstrated that DNA methylation (DNAm) plays an important role in Alzheimer’s disease (AD) and that DNAm differences can be detected in the blood of AD subjects. Most studies have correl...

    Authors: Wei Zhang, Juan I. Young, Lissette Gomez, Michael A. Schmidt, David Lukacsovich, Achintya Varma, X. Steven Chen, Eden R. Martin and Lily Wang
    Citation: Alzheimer's Research & Therapy 2023 15:78
    Content type: Research Published on:

  33. Alzheimer’s disease (AD) is the 5th leading cause of death in people 65 years and older. The ATN classification reflects a biological definition of AD pathology with markers of Aβ deposition (A), pathologic ta...

    Authors: Mélina Régy, Aline Dugravot, Séverine Sabia, Elodie Bouaziz-Amar, Claire Paquet, Bernard Hanseeuw, Archana Singh-Manoux and Julien Dumurgier
    Citation: Alzheimer's Research & Therapy 2023 15:77
    Content type: Research Published on:

  34. Advances in pharmacological and non-pharmacological dementia interventions may mean future dementia prevention incorporates a combination of targeted screening and lifestyle modifications. Elucidating potentia...

    Authors: Nikki-Anne Wilson, Ruth Peters, Nicola T. Lautenschlager and Kaarin J. Anstey
    Citation: Alzheimer's Research & Therapy 2023 15:76
    Content type: Research Published on:

  35. Vascular dysfunction, including cerebral hypoperfusion, plays an important role in the pathogenesis and progression of Alzheimer’s disease (AD), independent of amyloid and tau pathology. We established an AD-r...

    Authors: Meng Meng, Fang Liu, Yilong Ma, Wen Qin, Lining Guo, Shichun Peng, Marc L. Gordon, Yue Wang and Nan Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:75
    Content type: Research Published on:

  36. Plasma neurofilament light (NfL) is an indicator of neurodegeneration and/or neuroaxonal injury in persons with Alzheimer’s disease (AD) and a wide range of other neurological disorders. Here, we characterized...

    Authors: Michael Malek-Ahmadi, Yi Su, Valentina Ghisays, Ji Luo, Vivek Devadas, Yinghua Chen, Wendy Lee, Hillary Protas, Kewei Chen, Henrik Zetterberg, Kaj Blennow, Richard J. Caselli and Eric M. Reiman
    Citation: Alzheimer's Research & Therapy 2023 15:74
    Content type: Research Published on:

  38. In the context of the development of pharmaceutical interventions, expectations and experiences of participants are essential. Their insights may be particularly helpful to address the challenges of recruiting...

    Authors: Lois Ottenhoff, Everard G. B. Vijverberg, Leonie N. C. Visser, Merike Verijp, Niels D. Prins, Wiesje M. Van der Flier and Sietske A. M. Sikkes
    Citation: Alzheimer's Research & Therapy 2023 15:72
    Content type: Research Published on:

  39. Neuroinflammation, characterized by increased reactivity of microglia and astrocytes in the brain, is known to be present at various stages of the Alzheimer’s disease (AD) continuum. However, its presence and rel...

    Authors: Anniina Snellman, Laura L. Ekblad, Jouni Tuisku, Mikko Koivumäki, Nicholas J. Ashton, Juan Lantero-Rodriguez, Thomas K. Karikari, Semi Helin, Marco Bucci, Eliisa Löyttyniemi, Riitta Parkkola, Mira Karrasch, Michael Schöll, Henrik Zetterberg, Kaj Blennow and Juha O. Rinne
    Citation: Alzheimer's Research & Therapy 2023 15:71
    Content type: Research Published on:

  40. There is a need for a reliable, easy-to-use, widely available, and validated tool for timely cognitive impairment identification. We created a computerized cognitive screening tool (Santé-Cerveau digital tool ...

    Authors: Constance Lesoil, Stéphanie Bombois, Octave Guinebretiere, Marion Houot, Mahsa Bahrami, Marcel Levy, Rémy Genthon, Frédérique Bozon, Heidy Jean-Marie, Stéphane Epelbaum, Pierre Foulon, Nicolas Villain and Bruno Dubois
    Citation: Alzheimer's Research & Therapy 2023 15:70
    Content type: Research Published on:

  41. Previous studies have suggested a correlation between elevated levels of β2-microglobulin (B2M) and cognitive impairment. However, the existing evidence is insufficient to establish a conclusive relationship. Thi...

    Authors: Yi-Ming Huang, Ya-Hui Ma, Pei-Yang Gao, Zhi-Bo Wang, Liang-Yu Huang, Jia-Hui Hou, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2023 15:69
    Content type: Research Published on:

  42. A growing body of evidence shows differences in the prevalence of cardiometabolic syndrome (CMS) and dementia based on gender and ethnicity. However, there is a paucity of information about ethnic- and gender-...

    Authors: Sung Hoon Kang, Mengting Liu, Gilsoon Park, Sharon Y. Kim, Hyejoo Lee, William Matloff, Lu Zhao, Heejin Yoo, Jun Pyo Kim, Hyemin Jang, Hee Jin Kim, Neda Jahanshad, Kyumgmi Oh, Seong-Beom Koh, Duk L. Na, John Gallacher…
    Citation: Alzheimer's Research & Therapy 2023 15:68
    Content type: Research Published on:

  43. Individuals from minority ethnic groups in the UK are thought to be at higher risk of developing dementia while facing additional barriers to receiving timely care. However, few studies in the UK have examined...

    Authors: Melissa Co, Christoph Mueller, Rosie Mayston, Jayati Das-Munshi and Matthew Prina
    Citation: Alzheimer's Research & Therapy 2023 15:67
    Content type: Research Published on:

  44. Both Alzheimer’s disease (AD) genetic risk factors and indices of cognitive reserve (CR) influence risk of cognitive decline, but it remains unclear whether they interact. This study examined whether a CR inde...

    Authors: Corinne Pettigrew, Jurijs Nazarovs, Anja Soldan, Vikas Singh, Jiangxia Wang, Timothy Hohman, Logan Dumitrescu, Julia Libby, Brian Kunkle, Alden L. Gross, Sterling Johnson, Qiongshi Lu, Corinne Engelman, Colin L. Masters, Paul Maruff, Simon M. Laws…
    Citation: Alzheimer's Research & Therapy 2023 15:66
    Content type: Research Published on:

  45. The use of music interventions as a non-pharmacological therapy to improve cognitive and behavioral symptoms in Alzheimer’s disease (AD) patients has gained popularity in recent years, but the evidence for the...

    Authors: Malak Bleibel, Ali El Cheikh, Najwane Said Sadier and Linda Abou-Abbas
    Citation: Alzheimer's Research & Therapy 2023 15:65
    Content type: Review Published on:

  46. Aβ42/Aβ40 ratios in cerebrospinal fluid (CSF) and blood are reduced in preclinical Alzheimer’s disease (AD), but their temporal and correlative relationship with cerebral Aβ pathology at this early disease sta...

    Authors: Emelie Andersson, Nina Schultz, Takashi Saito, Takaomi C. Saido, Kaj Blennow, Gunnar K. Gouras, Henrik Zetterberg and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2023 15:64
    Content type: Research Published on:

  47. Authors: Francesca Conca, Valentina Esposito, Francesco Rundo, Davide Quaranta, Cristina Muscio, Rosa Manenti, Giulia Caruso, Ugo Lucca, Alessia Antonella Galbussera, Sonia Di Tella, Francesca Baglio, Federica L’Abbate, Elisa Canu, Valentina Catania, Massimo Filippi, Giulia Mattavelli…
    Citation: Alzheimer's Research & Therapy 2023 15:63
    Content type: Correction Published on:

    The original article was published in Alzheimer's Research & Therapy 2022 14:113

  48. Loss of synaptic functionality has been recently identified as an early-stage indicator of neurological diseases. Consequently, monitoring changes in synaptic protein levels may be relevant for observing disea...

    Authors: Shreyasee Das, Julie Goossens, Dirk Jacobs, Nele Dewit, Yolande A. L. Pijnenburg, Sjors G. J. G. In ‘t Veld, Charlotte E. Teunissen and Eugeen Vanmechelen
    Citation: Alzheimer's Research & Therapy 2023 15:62
    Content type: Research Published on:

  49. Connectome mapping may reveal new treatment targets for patients with neurological and psychiatric diseases. However, the long-term delayed recall based-network with structural and functional connectome is sti...

    Authors: Jie Ma, Mou-Xiong Zheng, Jia-Jia Wu, Xiang-Xin Xing, Yun-Ting Xiang, Dong Wei, Xin Xue, Han Zhang, Xu-Yun Hua, Qi-Hao Guo and Jian-Guang Xu
    Citation: Alzheimer's Research & Therapy 2023 15:61
    Content type: Research Published on:

  50. Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will need to be made. While identifying preferred therapeut...

    Authors: George Dranitsaris, Quanwu Zhang, Lin Mu, Christopher Weyrer, Erik Drysdale, Peter Neumann, Alireza Atri and Amir Abbas Tahami Monfared
    Citation: Alzheimer's Research & Therapy 2023 15:60
    Content type: Research Published on:
Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193